BioCentury | Mar 9, 2018
Company News

DNDi, partners aim to bring cheaper HCV combo to Latin America

...and Sovaldi sofosbuvir is less than $500. Under the agreement, the Pharco Pharmaceuticals unit of Pharco Corp....
...Aires, Argentina) will collaborate on advocacy efforts to increase patient access to affordable HCV treatment. Pharco...
...At the time, Pharco agreed to price the regimen at $294 or less per treatment. Pharco...
BioCentury | Mar 7, 2018
Company News

DNDi, partners aim to bring cheaper HCV combo to Latin America

...and Sovaldi sofosbuvir is less than $500. Under the agreement, the Pharco Pharmaceuticals unit of Pharco Corp....
...Mundo Sano will collaborate on advocacy efforts to increase patient access to affordable HCV treatment. Pharco...
...At the time, Pharco agreed to price the regimen at $294 or less per treatment. Pharco...
BioCentury | Apr 15, 2016
Politics & Policy

DNDi aims to develop $300-per-course HCV regimen

...pan-genotypic HCV therapy for low- and middle-income countries, the Drugs for Neglected Diseases initiative said Pharco Corp....
...$300 per course of treatment. The trials are set to start this year. DNDi said Pharco...
...will also price the regimen commercially at $294 or less per treatment course, if approved. Pharco...
BioCentury | Dec 7, 2015
Clinical News

Ravidasvir: Phase III data

...presented at the American Association for the Study of Liver Diseases meeting in San Francisco. Pharco...
...ravidasvir in Egypt (see BioCentury, Dec. 8, 2014). Presidio Pharmaceuticals Inc. , San Francisco, Calif. Pharco Corp....
BioCentury | Oct 26, 2015
Financial News

Naia completes venture financing

...Greenbrae, Calif. Business: Endocrine/Metabolic, Gastrointestinal Date completed: 2015-10-19 Type: Venture financing Raised: $5.3 million Investors: Pharco Corp....
BioCentury | Dec 8, 2014
Company News

Presidio, Pharco deal

...Presidio granted Pharco exclusive rights to develop and commercialize Phase II HCV product PPI-668 in Egypt...
...expand the territory to include additional countries in the Middle East and North Africa region. Pharco...
...will receive an upfront payment and will be eligible for development milestones and tiered royalties. Pharco...
Items per page:
1 - 6 of 6
BioCentury | Mar 9, 2018
Company News

DNDi, partners aim to bring cheaper HCV combo to Latin America

...and Sovaldi sofosbuvir is less than $500. Under the agreement, the Pharco Pharmaceuticals unit of Pharco Corp....
...Aires, Argentina) will collaborate on advocacy efforts to increase patient access to affordable HCV treatment. Pharco...
...At the time, Pharco agreed to price the regimen at $294 or less per treatment. Pharco...
BioCentury | Mar 7, 2018
Company News

DNDi, partners aim to bring cheaper HCV combo to Latin America

...and Sovaldi sofosbuvir is less than $500. Under the agreement, the Pharco Pharmaceuticals unit of Pharco Corp....
...Mundo Sano will collaborate on advocacy efforts to increase patient access to affordable HCV treatment. Pharco...
...At the time, Pharco agreed to price the regimen at $294 or less per treatment. Pharco...
BioCentury | Apr 15, 2016
Politics & Policy

DNDi aims to develop $300-per-course HCV regimen

...pan-genotypic HCV therapy for low- and middle-income countries, the Drugs for Neglected Diseases initiative said Pharco Corp....
...$300 per course of treatment. The trials are set to start this year. DNDi said Pharco...
...will also price the regimen commercially at $294 or less per treatment course, if approved. Pharco...
BioCentury | Dec 7, 2015
Clinical News

Ravidasvir: Phase III data

...presented at the American Association for the Study of Liver Diseases meeting in San Francisco. Pharco...
...ravidasvir in Egypt (see BioCentury, Dec. 8, 2014). Presidio Pharmaceuticals Inc. , San Francisco, Calif. Pharco Corp....
BioCentury | Oct 26, 2015
Financial News

Naia completes venture financing

...Greenbrae, Calif. Business: Endocrine/Metabolic, Gastrointestinal Date completed: 2015-10-19 Type: Venture financing Raised: $5.3 million Investors: Pharco Corp....
BioCentury | Dec 8, 2014
Company News

Presidio, Pharco deal

...Presidio granted Pharco exclusive rights to develop and commercialize Phase II HCV product PPI-668 in Egypt...
...expand the territory to include additional countries in the Middle East and North Africa region. Pharco...
...will receive an upfront payment and will be eligible for development milestones and tiered royalties. Pharco...
Items per page:
1 - 6 of 6